Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and price targets for Bolt Biotherapeutics and Lipella Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Lipella Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Bolt Biotherapeutics presently has a consensus price target of $14.50, suggesting a potential upside of 271.79%. Given Bolt Biotherapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Bolt Biotherapeutics is more favorable than Lipella Pharmaceuticals.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bolt Biotherapeutics | $4.70 million | 1.60 | -$33.38 million | ($16.44) | -0.24 |
| Lipella Pharmaceuticals | $536,357.00 | 0.00 | -$5.02 million | ($2.42) | -0.00 |
Lipella Pharmaceuticals has lower revenue, but higher earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Bolt Biotherapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
Profitability
This table compares Bolt Biotherapeutics and Lipella Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
| Lipella Pharmaceuticals | -988.83% | -224.08% | -172.88% |
Summary
Bolt Biotherapeutics beats Lipella Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
